A Phase 1/1b/2a, 3-Part, Open-Label, Multicentre Study To Assess The Safety, Tolerability, Pharmacokinetics And Preliminary Antitumor Activity Of Ascending Doses Of AZD5991 In Subjects With Relapsed Or Refractory Haematologic Malignancies